The Global Fund Welcomes Commitment by the United States to Expand Access to Lenacapavir
04 September 2025
WASHINGTON D.C./GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) welcomes the commitment by the United States (U.S.) to expand access to lenacapavir, a breakthrough HIV prevention drug, in low- and middle-income countries.
In July, the Global Fund announced an agreement with Gilead to secure access to lenacapavir, which has the potential to transform HIV prevention worldwide. With today’s announcement, the U.S. has expressed interest to work with the Global Fund as a key partner to jointly plan for the efficient rollout of lenacapavir in countries with significant HIV burden.
Working together, the U.S., the Global Fund and Gilead will maximize the impact of this American innovation by helping countries drive down new HIV infections, particularly amongst the most vulnerable. This collaboration will emphasize country-driven planning to ensure national programs can integrate lenacapavir into their HIV prevention strategies in the most efficient, effective (or impactful) and sustainable way.
“Accelerating access to innovations like lenacapavir is imperative if we are to turn the tide against HIV,” said Peter Sands, Executive Director of the Global Fund. “We must ensure that breakthrough tools are deployed rapidly, affordably, and in the most impactful way possible. By targeting where lenacapavir can have the greatest effect, and working with the U.S. and Gilead, we can help countries integrate it efficiently into their HIV prevention programs – reducing new infections and enabling them to move more quickly along the pathway toward transition and self-reliance.”
Scaling up the use of lenacapavir is poised to be a gamechanger in the fight against HIV. The Global Fund is committed to supporting country-driven approaches, shaping drug and health product markets to ensure affordability, and working with partners to maximize impact. The Global Fund continues to accompany countries on their pathway to stronger, nationally led and sustainably financed health systems.